← All organizations
Highest phase reached
Phase 4
First clinical trial
Jan 1, 2004Last known activity
Sep 2, 2021
Timeline
1990s
- Jan 1, 1999
James Graham Brown Cancer Center— Founded
Drugs by trial phase (56 distinct, 33 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 2 (38 own, 0 via acquisition)
Phase 1 (16 own, 0 via acquisition)
Other trials (1 own, 0 via acquisition)
Indications
Studied for
- Anemia
- Breakthrough Pain
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Small Cell
- Colonic Neoplasms
- Exanthema
- Glioblastoma
- Head and Neck Neoplasms
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, T-Cell
- Lung Neoplasms
- Lymphoma
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Cutaneous
- Melanoma
- Mucositis
- Multiple Myeloma
- Mycoses
- Mycosis Fungoides
- Neoplasm Metastasis
- Neoplasms
- Neoplasms, Plasma Cell
- Neoplasms, Second Primary
- Osteomyelitis
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Peritoneal Neoplasms
- Prostatic Neoplasms
- Sezary Syndrome
- Small Cell Lung Carcinoma
- Stomatitis
- Thrombocytopenia
- Uterine Cervical Neoplasms
Recent trials (45)
- NCT04990921CollaboratorPhase 2Sep 2, 2021
- NCT02990416CollaboratorPhase 1/Phase 2Jan 1, 2017
- NCT01839552Lead sponsorPhase 4Oct 1, 2014
- NCT01985087Lead sponsorPhase 1/Phase 2Sep 1, 2014
- NCT02143050Overall official - principal investigatorPhase 1/Phase 2Sep 1, 2014
- NCT01985087Overall official - principal investigatorPhase 1/Phase 2Sep 1, 2014
- NCT02143050Lead sponsorPhase 1/Phase 2Sep 1, 2014
- NCT02128100Lead sponsorPhase 2May 1, 2014
- NCT02128100Overall official - principal investigatorPhase 2May 1, 2014
- NCT02099240CollaboratorEarly Phase 1Apr 1, 2014
- NCT01871454Lead sponsorPhase 2Oct 1, 2013
- NCT01874860Overall official - principal investigatorPhase 1Aug 1, 2013
- NCT01874860Lead sponsorPhase 1Aug 1, 2013
- NCT01772719Lead sponsorN/AAug 1, 2012
- NCT01668849Lead sponsorPhase 1Aug 1, 2012
Details
- Founded
- Louisville, KY, US Jan 1, 1999
- Last known activity
- Sep 2, 2021